Analysis of Clinical Features and GNPTAB Gene Mutation Variability in Chinese Individuals with Mucolipidosis Type II α/β
-
By
-
Xiaoming Gan
-
Jieling Li
-
Jie Cao
-
July 21, 2026
Clinical Scorecard: Analysis of Clinical Features and GNPTAB Gene Mutation Variability in Chinese Individuals with Mucolipidosis Type II α/β
At a Glance
| Category | Detail |
|---|
| Condition | Mucolipidosis Type II α/β |
| Key Mechanisms | Caused by mutations in the GNPTAB gene leading to GlcNAc-1-phosphotransferase deficiency. |
| Target Population | Chinese patients with ML II α/β |
| Care Setting | Clinical diagnosis and genetic counseling |
Key Highlights
- 100% of patients presented with skeletal deformities.
- Median age at diagnosis was 17.5 months.
- Most common mutation found in 39.3% of patients.
- Significant comorbidities include cardiac abnormalities (16.1%) and pulmonary complications (12.5%).
- High mortality rate primarily due to respiratory failure.
Guideline-Based Recommendations
Diagnosis
- Diagnosis based on clinical severity, biochemical enzyme testing, and genetic interpretation.
Management
- Genetic counseling and targeted molecular screening.
Monitoring & Follow-up
- Regular monitoring of respiratory function and developmental milestones.
Risks
- High risk of premature death due to respiratory failure or severe infection.
Patient & Prescribing Data
Chinese individuals diagnosed with ML II α/β.
Focus on early diagnosis and management of complications.
Clinical Best Practices
- Utilize whole-exome sequencing for genetic diagnosis.
- Consider ethnicity-specific mutation patterns in genetic screening.
- Implement early intervention strategies for developmental delays.
Related Resources & Content
